The MASTER registry on venous thromboembolism: Description of the study cohort

Agnelli, Giancarlo; Verso, Melina; Ageno, Walter; Imberti, Davide; Moia, Marco; Palareti, Gualtiero; Rossi, Romina; Pistelli, Riccardo

doi:10.1016/j.thromres.2007.06.009

Cited by 87 publications

(86 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Full copies of 80 potentially appropriate studies and two abstracts (neither the manuscript nor the abstract could be retrieved for one article) were retrieved [7]. Eight additional articles and one additional abstract (a duplicate publication) were subsequently identified [8][9][10][11][12][13][14][15][16]. After excluding articles not meeting the prespecified inclusion criteria, a total of 25 studies were considered for the final analysis [8][9][10].…”

Section: Resultsmentioning

confidence: 99%

Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review

Squizzato¹,

Galli²,

Dentali³

et al. 2009

European Respiratory Journal

View full text Add to dashboard Cite

The published literature regarding the safety of outpatient treatment of symptomatic pulmonary embolism (PE) was systematically summarised.A literature search was performed using the PubMed and EMBASE databases. Studies in which patients had symptomatic PE and the antithrombotic treatment was administered completely at home or the patients were discharged early were selected. A scoring system was used to divide studies into three quality categories. Short-and long-term outcomes were extracted: all-cause mortality, death from PE or from major haemorrhage, recurrent venous thromboembolism, and major bleeding.Eleven observational studies were included. No randomised controlled studies were identified. No study fulfilled the criteria for high quality. A total of 928 patients with symptomatic PE were treated completely as outpatients or discharged early; haemodynamic instability and hypoxia were the main exclusion criteria. No patient died during the first 7 days of antithrombotic treatment.Outpatient treatment of symptomatic PE is not based on high-quality evidence. Although the published data suggest that certain subgroups of haemodynamically and respiratorily stable patients may be safely treated at home when a well-defined management programme is applied, further studies are warranted for a short-term prognostic risk stratification of this PE subgroup.

show abstract

Section: Resultsmentioning

confidence: 99%

Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review

Squizzato¹,

Galli²,

Dentali³

et al. 2009

European Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…For cancer patients on active treatment who develop vte, therapy with low molecular weight heparin (lmwh) is more effective than therapy with warfarin in preventing recurrent blood clots 10 . The clot trial-which included 672 cancer patients with acute symptomatic proximal dvt, pulmonary embolism (pe), or both-compared lmwh with warfarin.…”

Section: Low Molecular Weight Heparinmentioning

confidence: 99%

Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment

Easaw¹,

Shea‐Budgell²,

Wu³

et al. 2015

Curr. Oncol.

View full text Add to dashboard Cite

Patients with cancer are at increased risk of venous thromboembolism (vte). Anticoagulation therapy is used to treat vte; however, patients with cancer have unique clinical circumstances that can often make decisions surrounding the administration of therapeutic anticoagulation complicated. No national Canadian guidelines on the management of established cancer-associated thrombosis have been published. We therefore aimed to develop a consensus-based, evidence-informed guideline on the topic.PubMed was searched for clinical trials and meta-analyses published between 2002 and 2013. Reference lists of key articles were hand-searched for additional publications. Content experts from across Canada were assembled to review the evidence and make recommendations.Low molecular weight heparin is the treatment of choice for cancer patients with established vte. Direct oral anticoagulants are not recommended for the treatment of vte at this time. Specific clinical scenarios, including the presence of an indwelling venous catheter, renal insufficiency, and thrombocytopenia, warrant modifications in the therapeutic administration of anticoagulation therapy. Patients with recurrent vte should receive extended (>3 months) anticoagulant therapy. Incidental vte should generally be treated in the same manner as symptomatic vte. There is no evidence to support the monitoring of anti–factor Xa levels in clinically stable cancer patients receiving prophylactic anticoagulation; however, levels of anti–factor Xa could be checked at baseline and periodically thereafter in patients with renal insufficiency. Follow-up and education about the signs and symptoms of vte are important components of ongoing patient care.

show abstract

“…The signs and symptoms of dvt include pain, edema or swelling in the limbs or upper body, persistent cramping, and erythema. The signs and symptoms of pe include, but are not limited to, chest pain, shortness of breath, hypoxia, tachycardia, and tachypnea 42 . It is important to note that none of the signs or symptoms of dvt and pe are sensitive or specific for vte, and that the index of suspicion should be high when patients with these symptoms also have a substantial risk for vte (such as the presence of cancer).…”

Section: Treatment Of Established Vte In Ambulatory Patients With Solmentioning

confidence: 99%

“…In addition to a clinical evaluation, imaging is required to diagnose dvt (that is, ultrasonography) and pe (that is, pe-protocol computed tomography imaging, ventilation-perfusion scan) 43 . Initial therapy for established vte in cancer patients should be a low molecular weight heparin (lmwh) [42][43][44][45] .…”

Section: Treatment Of Established Vte In Ambulatory Patients With Solmentioning

confidence: 99%

Evidence-Based Guidance on Venous Thromboembolism in Patients with Solid Tumours

Shea‐Budgell

Easaw

2014

Current Oncology

View full text Add to dashboard Cite

Venous thromboembolism (vte) is a serious, life-threatening complication of cancer. Anticoagulation therapy such as low molecular weight heparin (lmwh) has been shown to treat and prevent vte. Cancer therapy is often complex and ongoing, making the management of vte less straightforward in patients with cancer. There are no published Canadian guidelines available to suggest appropriate strategies for the management of vte in patients with solid tumours. We therefore aimed to develop a clear, evidence-based guideline on this topic. A systematic review of clinical trials and meta-analyses published between 2002 and 2013 in PubMed was conducted. Reference lists were handsearched for additional publications. The National Guidelines Clearinghouse was searched for relevant guidelines. Recommendations were developed based on the best available evidence. In patients with solid tumours, lmwh is recommended for those with established vte and for those without established vte but with a high risk for developing vte. Options for lmwh include dalteparin, enoxaparin, and tinzaparin. No one agent can be recommended over another, but in the setting of renal insufficiency, tinzaparin is preferred. Unfractionated heparin can be used under select circumstances only (that is, when rapid clearance of the anticoagulant is desired). The most common adverse event is bleeding, but major events are rare, and with appropriate follow-up care, bleeding can be monitored and appropriately managed.

show abstract

The MASTER registry on venous thromboembolism: Description of the study cohort

Cited by 87 publications

References 15 publications

Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review

Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review

Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment

Evidence-Based Guidance on Venous Thromboembolism in Patients with Solid Tumours

Contact Info

Product

Resources

About